3-Chloro-4-ethoxybenzeneacetyl chloride | 373361-72-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-Chloro-4-ethoxybenzeneacetyl chloride
• 英文别名: 2-(3-chloro-4-ethoxyphenyl)acetyl chloride
• CAS: 373361-72-9
• 化学式: C₁₀H₁₀Cl₂O₂
• 分子量: 233.09
• InChiKey: YGIBGLUYNJLKJL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• INDAZOLES SUBSTITUTED WITH1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION
  申请人：——

  公开号：US20030149034A1

  公开（公告）日：2003-08-07

  The present invention relates to an indazole derivative, pharmaceutically acceptable salt, solvated product and isomer thereof substituted with 1,1-dioxoisothiazolidine which are useful as inhibitors for Cyclin Dependent Kinase (CDK). The present invention also relates to an agent for inhibiting and treating diseases involving cell proliferation, e.g., cancer, inflammation, restenosis, angiogenesis, etc. which comprises the compound of formula (1) as an active ingredient together with a pharmaceutically acceptable carrier.

  本发明涉及一种与1,1-二氧异噻唑啉基取代的吲唑啉衍生物、药用可接受的盐、溶剂化产物和同分异构体，其作为 Cyclin Dependent Kinase (CDK) 的抑制剂。本发明还涉及一种用于抑制和治疗涉及细胞增殖的疾病，例如癌症、炎症、再狭窄、血管生成等的药剂，其包括化合物（1）的配方作为活性成分，与药用可接受的载体一起使用。
• EP1280802A4
  申请人：——

  公开号：EP1280802A4

  公开（公告）日：2003-06-11
• INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION
  申请人：LG Life Sciences Ltd.

  公开号：EP1280802A1

  公开（公告）日：2003-02-05
• US6620831B2
  申请人：——

  公开号：US6620831B2

  公开（公告）日：2003-09-16
• [EN] INDAZOLES SUBSTITUTED WITH 1,1-DIOXOISOTHIAZOLIDINE USEFUL AS INHIBITORS OF CELL PROLIFERATION<br/>[FR] INDAZOLES SUBSTITUES AVEC DE LA 1,1-DIOXOISOTHIAZOLIDINE UTILES COMME INHIBITEURS DE LA PROLIFERATION CELLULAIRE
  申请人：LG CHEM INVESTMENT LTD

  公开号：WO2001085726A1

  公开（公告）日：2001-11-15

  The present invention relates to an indazole derivative, pharmaceutically acceptable salt, solvated product and isomer thereof substituted with 1,1-dioxoisothiazolidine which are useful as inhibitors for Cyclin Dependent Kinase(CDK). The present invention also relates to an agent for inhibiting and treating diseases involving cell proliferation, e.g., cancer, inflammation, restenosis, angiogenesis, etc. which comprises the indazole derivative as an active ingredient together with a pharmaceutically acceptable carrier.